2026: The time for AI to really deliver
In 2026, clinical trial design will be reshaped by artificial intelligence (AI)-powered simulation and richer clinical and real-world data. Improvements …
Post
-
-
Nxera reports positive outcomes for daridorexant Phase III insomnia study
Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50mg, aimed at treating insomnia in …
-
JPM26: Immunocore Signals Entry into Type 1 Diabetes
At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on 14th January 2026, Immunocore outlined 2026 strategic priorities …
-
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its …
-
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK) showed over 15 …
-
OrsoBio announces clinical trial progress for TLC-2716 metabolic therapy
OrsoBio has announced the publication in Nature Medicine of Phase I clinical trial data for TLC-2716, an oral liver-targeted inverse …
-
Genmab reports top line results in Phase III DLBCL trial
Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival …
-
Speech biomarkers offer new lease of life to patient experience and trial retention
Biomarkers remain a critical measurement in almost every clinical trial, with this type of data facilitating the accurate characterisation of …
-
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining …
-
The advantages of a platform approach in clinical trial data management
Clinical trials are producing more data than ever before, drawing from vast and diverse datasets that must be cleaned and …
-
Ocugen sets sights on Phase III after GA gene therapy win
Ocugen has posted positive results for its lead investigational gene therapy, OCU410, in geographic atrophy (GA) secondary to dry age-related …
-
QPS adopts Oracle Argus to advance safety in clinical trials
US-based contract research organisation QPS Holdings (QPS) has implemented a new clinical trial pharmacovigilance system, Oracle Argus, to advance safety …
-
Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management
Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 (esreboxetine) for the management of fibromyalgia, with the first …
-
JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases
Leo Pharma’s bold commitment to be a strong player in the dermatological space was made clear at the J.P Morgan …
-
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death
Intellia Therapeutics is confident in the safety profile of its gene therapies after revealing that a man's death in a …
